Cargando…

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation

It is known that multiple myeloma (MM) cells express CD38 and that a recently developed human anti-CD38 monoclonal antibody Daratumumab mediates myeloma killing. However, the expression of CD38 and other functionally related ectoenzymes within the MM bone niche and the potential effects of Daratumum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Costa, Federica, Toscani, Denise, Chillemi, Antonella, Quarona, Valeria, Bolzoni, Marina, Marchica, Valentina, Vescovini, Rosanna, Mancini, Cristina, Martella, Eugenia, Campanini, Nicoletta, Schifano, Chiara, Bonomini, Sabrina, Accardi, Fabrizio, Horenstein, Alberto L., Aversa, Franco, Malavasi, Fabio, Giuliani, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593586/ https://www.ncbi.nlm.nih.gov/pubmed/28915615 http://dx.doi.org/10.18632/oncotarget.17896

Ejemplares similares

P58 LOW CD38 EXPRESSION BY PLASMA CELLS IN EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA PATIENTS
por: Notarfranchi, L., et al.
Publicado: (2023)

A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes
por: Horenstein, Alberto L, et al.
Publicado: (2013)

Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors
por: Horenstein, Alberto L., et al.
Publicado: (2018)

IL21R expressing CD14(+)CD16(+) monocytes expand in multiple myeloma patients leading to increased osteoclasts
por: Bolzoni, Marina, et al.
Publicado: (2017)

A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation
por: Morandi, Fabio, et al.
Publicado: (2015)

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
por: Morandi, Fabio, et al.
Publicado: (2018)

Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche
por: Chillemi, Antonella, et al.
Publicado: (2017)

The Circular Life of Human CD38: From Basic Science to Clinics and Back
por: Horenstein, Alberto L., et al.
Publicado: (2020)

PD-L1/PD-1 Axis in Multiple Myeloma Microenvironment and a Possible Link with CD38-Mediated Immune-Suppression
por: Costa, Federica, et al.
Publicado: (2021)

Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients
por: Marchica, Valentina, et al.
Publicado: (2019)

CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy
por: Horenstein, Alberto L., et al.
Publicado: (2019)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020)

Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties
por: Costa, Federica, et al.
Publicado: (2017)

NAD(+)-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model
por: Horenstein, Alberto L., et al.
Publicado: (2015)

Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model
por: Zannetti, Beatrice Anna, et al.
Publicado: (2020)

The CD38/CD157 mammalian gene family: An evolutionary paradigm for other leukocyte surface enzymes
por: Deaglio, Silvia, et al.
Publicado: (2006)

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling
por: Accardi, Fabrizio, et al.
Publicado: (2015)

Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy
por: Marchica, Valentina, et al.
Publicado: (2020)

Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo
por: Fumey, William, et al.
Publicado: (2017)

Cd38/Adp-Ribosyl Cyclase: A New Role in the Regulation of Osteoclastic Bone Resorption
por: Sun, Li, et al.
Publicado: (1999)

CD38 Ligation in Peripheral Blood Mononuclear Cells of Myeloma Patients Induces Release of Protumorigenic IL-6 and Impaired Secretion of IFNγ Cytokines and Proliferation
por: Fedele, Giorgio, et al.
Publicado: (2013)

CD38 in Neurodegeneration and Neuroinflammation
por: Guerreiro, Serge, et al.
Publicado: (2020)

Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque
por: Ferrero, Enza, et al.
Publicado: (2004)

Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
por: Plesner, Torben, et al.
Publicado: (2020)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
por: Bisht, Kamlesh, et al.
Publicado: (2023)

The role of CD38 in HIV infection
por: Lu, Liqi, et al.
Publicado: (2021)

CD38 in Advanced Prostate Cancers
por: Guo, Christina, et al.
Publicado: (2021)

Targeting CD38 for acute leukemia
por: Zhong, Xushu, et al.
Publicado: (2022)

EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma
por: Chemlal, Djamila, et al.
Publicado: (2023)

Interferon gamma selectively inhibits very primitive CD342+CD38- and not more mature CD34+CD38+ human hematopoietic progenitor cells
Publicado: (1994)

CD38: T Cell Immuno-Metabolic Modulator
por: Kar, Anwesha, et al.
Publicado: (2020)

Roles of CD38 in the Immune Response to Infection
por: Glaría, Estibaliz, et al.
Publicado: (2020)

CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity
por: Piedra-Quintero, Zayda L., et al.
Publicado: (2020)

Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma
por: Kinder, Michelle, et al.
Publicado: (2021)

Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma
por: Lam, Jian Hang, et al.
Publicado: (2019)

CD38, CD157, and RAGE as Molecular Determinants for Social Behavior
por: Higashida, Haruhiro, et al.
Publicado: (2019)

Increased expression of the ectoenzyme CD38 in peripheral blood plasmablasts and plasma cells of patients with systemic sclerosis
por: Agarbati, S., et al.
Publicado: (2022)

Decreased levels of T follicular helper (CD4+CXCR5+) cells and CD27+CD38+ and CD27+CD38− B cells in ankylosing spondylitis patients correlate with markers of inflammation
por: Lejon, Kristina, et al.
Publicado: (2022)

Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma
por: Fayon, Maxime, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q7jmrc7135g3l4h856c7htpno6